President and Chief Executive Officer — Shawn K. Singh Chief Operating Officer — Joshua S. Prince Vice President, Corporate Development & Investor Relations — Mark McPartland Need a quote from a ...

Q3 2026 Management View Shawn Singh, President and CEO, highlighted the completion of the randomized portion of the PALISADE-3 Phase III trial in social anxiety disorder as a key milestone, stating ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates ...

Vistagen Therapeutics Inc (VTGN) advances its neuroscience and women's health programs while addressing challenges in clinical trials and regulatory strategies.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Vistagen Therapeutics (NASDAQ: VTGN) just disclosed its Q3 earnings on Thursday, February 12, 2026 at 04:20 PM. Here's a brief overview of the earnings report. Vistagen Therapeutics missed estimated ...

VistaGen’s beleaguered social anxiety spray may be back on hold, but that hasn’t stopped the biotech from touting separate open-label data that the company says show the therapy is safe and will work ...

The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of ----10(b) and 20(a) of the Securities ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 16, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel ...